IMMUNOMODULATORY THERAPY IN PATIENTS WITH UPPER RESPIRATORY TRACT INFECTIONS AND UPPER RESPIRATORY TRACT

Acute respiratory infections remain one of the most pressing health issues in our society, they form a high fraction of all infectious disease cases, and they pose a high risk of complications, among others these can affect upper respiratory tract (acute otitis media, evstaheit etc.), or exacerbate chronic diseases like chronic tonsilitis, and adenoiditis. Many patients have signs of secondary immune deficiency. In these cases affection of the upper respiratory tract is lingering with frequent relapses, and standard therapy is less effective. Supplementing the treatment regime with advanced immunomodulatory drug polyoksidonii reduces the treatment time for both acute inflammation of upper respiratory tract, and for exacerbation of chronic ENT pathology. It can also reduce the number of relapses during remission. A variety of forms and dosages provides the easy of use. Results of clinical studies confirm the high efficacy and safety